Tot Biopharm, a Suzhou-headquartered biotechnology firm backed by Chengwei Capital, has filed to list in Hong Kong under rules that allow pre-revenue biotech companies to list.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
